The 2021 ARCS Annual Conference held 7th-9th June brought together industry, regulator, academia and researchers to educate, network and unite in a time of change. Despite Melbourne going into lockdown, the conference delivered essential and timely information in each of the key educational areas – particularly as industry traverses the issues associated with the COVID-19 pandemic as well as other local and international issues. Speakers unable to join in person were brought via Zoom.
The theme for the conference “From pandemic to recovery – building Australia’s competitive advantage post COVID”, brought together a strong line up of international speakers giving a global perspective joined by high profile Australian experts. Delegates came from a cross section of the healthcare sector and industry and including senior executives, government officials through to recent graduates.
As the largest conference on regulation, reimbursement, clinical research and utilisation of new medical technologies and therapeutics in Australia/New Zealand, ARCS Australia CEO Shanny Dyer speaks about the mitigation and planning required to deliver an in-person conference during the pandemic. Shanny also talks the need to recognise the work delivered by exceptional individuals and organisations through industry awards, which were announced during a dinner event mid-way through the conference.
-
ARCS Virtual Summit 2020 Report
ANDHealth CEO Bronwyn Le Grice steps us through key report data from 317 emerging high growth potential digital health companies across Australia. Each of these companies has been supported in some way by ANDHealth since 2017.
-
ARCS Annual Conference 2019
Earlier this month, ARCS Australia held it’s Annual Conference at the International Convention Centre Sydney – ICC Sydney, with the theme of putting patients at the centre of healthcare. Uniquely, the conference included a number of patients who attended, presented or were referenced.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
